184 related articles for article (PubMed ID: 28883001)
41. A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer.
Kaur S; Elkahloun AG; Singh SP; Chen QR; Meerzaman DM; Song T; Manu N; Wu W; Mannan P; Garfield SH; Roberts DD
Oncotarget; 2016 Mar; 7(9):10133-52. PubMed ID: 26840086
[TBL] [Abstract][Full Text] [Related]
42. Sulforaphane Suppresses the Growth of Triple-negative Breast Cancer Stem-like Cells
Castro NP; Rangel MC; Merchant AS; MacKinnon G; Cuttitta F; Salomon DS; Kim YS
Cancer Prev Res (Phila); 2019 Mar; 12(3):147-158. PubMed ID: 30679159
[TBL] [Abstract][Full Text] [Related]
43. EGCG-Derivative G28 Shows High Efficacy Inhibiting the Mammosphere-Forming Capacity of Sensitive and Resistant TNBC Models.
Giró-Perafita A; Rabionet M; Planas M; Feliu L; Ciurana J; Ruiz-Martínez S; Puig T
Molecules; 2019 Mar; 24(6):. PubMed ID: 30875891
[TBL] [Abstract][Full Text] [Related]
44. Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression.
Anbalagan M; Sheng M; Fleischer B; Zhang Y; Gao Y; Hoang V; Matossian M; Burks HE; Burow ME; Collins-Burow BM; Hangauer D; Rowan BG
Mol Cancer Res; 2017 Nov; 15(11):1491-1502. PubMed ID: 28751463
[TBL] [Abstract][Full Text] [Related]
45. Benzo[
Kim YJ; Lee DH; Choi YS; Jeong JH; Kwon SH
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31775247
[TBL] [Abstract][Full Text] [Related]
46. Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma.
Nakagawa M; Fujita S; Katsumoto T; Yamagata K; Ogawara Y; Hattori A; Kagiyama Y; Honma D; Araki K; Inoue T; Kato A; Inaki K; Wada C; Ono Y; Yamamoto M; Miura O; Nakashima Y; Kitabayashi I
Cancer Sci; 2019 Jan; 110(1):194-208. PubMed ID: 30343511
[TBL] [Abstract][Full Text] [Related]
47. Downregulation of CXCR7 inhibits proliferative capacity and stem cell-like properties in breast cancer stem cells.
Tang X; Li X; Li Z; Liu Y; Yao L; Song S; Yang H; Li C
Tumour Biol; 2016 Oct; 37(10):13425-13433. PubMed ID: 27460092
[TBL] [Abstract][Full Text] [Related]
48. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer.
Weng YS; Tseng HY; Chen YA; Shen PC; Al Haq AT; Chen LM; Tung YC; Hsu HL
Mol Cancer; 2019 Mar; 18(1):42. PubMed ID: 30885232
[TBL] [Abstract][Full Text] [Related]
49. Knockdown of Musashi RNA Binding Proteins Decreases Radioresistance but Enhances Cell Motility and Invasion in Triple-Negative Breast Cancer.
Troschel FM; Minte A; Ismail YM; Kamal A; Abdullah MS; Ahmed SH; Deffner M; Kemper B; Kiesel L; Eich HT; Ibrahim SA; Götte M; Greve B
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32245259
[TBL] [Abstract][Full Text] [Related]
50. Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment.
Lu H; Tran L; Park Y; Chen I; Lan J; Xie Y; Semenza GL
Cancer Res; 2018 Aug; 78(15):4191-4202. PubMed ID: 29880481
[TBL] [Abstract][Full Text] [Related]
51. IKK inhibition by BMS-345541 suppresses breast tumorigenesis and metastases by targeting GD2+ cancer stem cells.
Battula VL; Nguyen K; Sun J; Pitner MK; Yuan B; Bartholomeusz C; Hail N; Andreeff M
Oncotarget; 2017 Jun; 8(23):36936-36949. PubMed ID: 28415808
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of Tumor Cell Growth and Cancer Stem Cell Expansion by a Bispecific Antibody Targeting EGFR and HER3.
Rau A; Lieb WS; Seifert O; Honer J; Birnstock D; Richter F; Aschmoneit N; Olayioye MA; Kontermann RE
Mol Cancer Ther; 2020 Jul; 19(7):1474-1485. PubMed ID: 32430487
[TBL] [Abstract][Full Text] [Related]
53. Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer.
Gagliardi M; Pitner MK; Park J; Xie X; Saso H; Larson RA; Sammons RM; Chen H; Wei C; Masuda H; Chauhan G; Kondo K; Tripathy D; Ueno NT; Dalby KN; Debeb BG; Bartholomeusz C
Sci Rep; 2020 May; 10(1):8537. PubMed ID: 32444778
[TBL] [Abstract][Full Text] [Related]
54. Estrogen Receptor β as a Therapeutic Target in Breast Cancer Stem Cells.
Ma R; Karthik GM; Lövrot J; Haglund F; Rosin G; Katchy A; Zhang X; Viberg L; Frisell J; Williams C; Linder S; Fredriksson I; Hartman J
J Natl Cancer Inst; 2017 Mar; 109(3):1-14. PubMed ID: 28376210
[TBL] [Abstract][Full Text] [Related]
55. Metabolic stress induces GD2
Jaggupilli A; Ly S; Nguyen K; Anand V; Yuan B; El-Dana F; Yan Y; Arvanitis Z; Piyarathna DWB; Putluri N; Piwnica-Worms H; Manning HC; Andreeff M; Battula VL
Br J Cancer; 2022 Mar; 126(4):615-627. PubMed ID: 34811508
[TBL] [Abstract][Full Text] [Related]
56. Induction of the stem-like cell regulator CD44 by Rho kinase inhibition contributes to the maintenance of colon cancer-initiating cells.
Ohata H; Ishiguro T; Aihara Y; Sato A; Sakai H; Sekine S; Taniguchi H; Akasu T; Fujita S; Nakagama H; Okamoto K
Cancer Res; 2012 Oct; 72(19):5101-10. PubMed ID: 23002207
[TBL] [Abstract][Full Text] [Related]
57. cIAP1 regulates the EGFR/Snai2 axis in triple-negative breast cancer cells.
Majorini MT; Manenti G; Mano M; De Cecco L; Conti A; Pinciroli P; Fontanella E; Tagliabue E; Chiodoni C; Colombo MP; Delia D; Lecis D
Cell Death Differ; 2018 Dec; 25(12):2147-2164. PubMed ID: 29674627
[TBL] [Abstract][Full Text] [Related]
58. RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer.
Liu Y; Burness ML; Martin-Trevino R; Guy J; Bai S; Harouaka R; Brooks MD; Shang L; Fox A; Luther TK; Davis A; Baker TL; Colacino J; Clouthier SG; Shao ZM; Wicha MS; Liu S
Clin Cancer Res; 2017 Jan; 23(2):514-522. PubMed ID: 28034904
[TBL] [Abstract][Full Text] [Related]
59. Combining radiation to EGFR and Bcl-2 blockade: a new approach to target cancer stem cells in head and neck squamous cell carcinoma.
Guy JB; Espenel S; Louati S; Gauthier A; Garcia MA; Vial N; Malésys C; Ardail D; Alphonse G; Wozny AS; Rodriguez-Lafrasse C; Magné N
J Cancer Res Clin Oncol; 2021 Jul; 147(7):1905-1916. PubMed ID: 33791846
[TBL] [Abstract][Full Text] [Related]
60. ERN1 and ALPK1 inhibit differentiation of bi-potential tumor-initiating cells in human breast cancer.
Strietz J; Stepputtis SS; Preca BT; Vannier C; Kim MM; Castro DJ; Au Q; Boerries M; Busch H; Aza-Blanc P; Heynen-Genel S; Bronsert P; Kuster B; Stickeler E; Brabletz T; Oshima RG; Maurer J
Oncotarget; 2016 Dec; 7(50):83278-83293. PubMed ID: 27829216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
